Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Assets (2019 - 2025)

Historic Return on Assets for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 0.84%.

  • UroGen Pharma's Return on Assets fell 4400.0% to 0.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.84%, marking a year-over-year decrease of 4400.0%. This contributed to the annual value of 0.55% for FY2024, which is 1000.0% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Return on Assets is 0.84%, which was down 4400.0% from 0.68% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Return on Assets ranged from a high of 0.4% in Q3 2024 and a low of 1.06% during Q1 2021
  • Over the past 5 years, UroGen Pharma's median Return on Assets value was 0.78% (recorded in 2021), while the average stood at 0.73%.
  • In the last 5 years, UroGen Pharma's Return on Assets plummeted by -5900bps in 2021 and then surged by 5800bps in 2024.
  • UroGen Pharma's Return on Assets (Quarter) stood at 0.87% in 2021, then grew by 5bps to 0.83% in 2022, then soared by 34bps to 0.55% in 2023, then grew by 21bps to 0.43% in 2024, then tumbled by -94bps to 0.84% in 2025.
  • Its Return on Assets was 0.84% in Q3 2025, compared to 0.68% in Q2 2025 and 0.52% in Q1 2025.